Sakamoto, Mari
Fukuda, Hiroki
Kim, Jiyoong
Ide, Tomomi
Kinugawa, Shintaro
Fukushima, Arata
Tsutsui, Hiroyuki
Ishii, Akira
Ito, Shin
Asanuma, Hiroshi
Asakura, Masanori
Washio, Takashi
Kitakaze, Masafumi
Article History
Received: 28 November 2017
Accepted: 21 February 2018
First Online: 5 March 2018
Competing Interests
: Nothing to disclose for M.S., H.F., J.K., T.I., S.K., A.F., A.I., S.I., H.A. and T.W. H.T. reports personal. fees from Astellas, Otsuka, Takeda, Daiichi-Sankyo, Tanabe-Mitsubishi, Boehringer Ingelheim, Novartis, Bayer, and Bristol Myers Squibb. M.A. reports personal fees from Bayer, Ono, Otsuka, Pfizer, Sanofi, and Takeda. M.K. reports grants from Japanese government, during the conduct of the study; grants from Japanese government, Japan Heart Foundation, Japan Cardiovascular Research Foundation, Novartis, and Nihon Kohden; grants. and personal fees from Asteras, Pfizer, Tanabe-Mitubishi, Ono, Astrazeneca and Kureha; personal fees from Daiichi-sankyo, Bayer, Kowa, MSD, Shionogi, Taisho-Toyama and Toaeiyo